188 related articles for article (PubMed ID: 17195451)
1. A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan.
Fujimoto K; Tomonaga M; Goto S
Anticancer Res; 2006; 26(6A):4015-8. PubMed ID: 17195451
[TBL] [Abstract][Full Text] [Related]
2. [Effects of lentinan in advanced or recurrent cases of gastric, colorectal, and breast cancer].
Taguchi T
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):387-93. PubMed ID: 6349538
[TBL] [Abstract][Full Text] [Related]
3. [Clinical trial of non-specific immunotherapy using Lentinan in advanced or recurrent gastric cancer].
Yoshino S; Oka M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2239-43. PubMed ID: 19106583
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous regression in recurrent epithelial ovarian cancer.
Fujiwaki R; Sawada K
Arch Gynecol Obstet; 2007 May; 275(5):389-91. PubMed ID: 17177031
[TBL] [Abstract][Full Text] [Related]
6. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
[TBL] [Abstract][Full Text] [Related]
7. [Successful treatment of a patient with recurrent ovarian cancer by lentinan combined with intraarterial 5FU].
Shimizu Y; Hasumi K; Chen JT; Hirai Y; Nakayama K; Teshima H; Hamada T; Fujimoto I; Yamauchi K; Masubuchi K
Nihon Gan Chiryo Gakkai Shi; 1989 Mar; 24(3):647-51. PubMed ID: 2768975
[TBL] [Abstract][Full Text] [Related]
8. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer.
Oba K; Kobayashi M; Matsui T; Kodera Y; Sakamoto J
Anticancer Res; 2009 Jul; 29(7):2739-45. PubMed ID: 19596954
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
10. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
11. [A case of advanced gastric cancer successfully treated with TS-1/CDDP combination chemotherapy, able to maintain CR for more than two years against multiple liver metastases].
Meguro E; Kimura T; Noda Y; Matsumoto Y; Irinoda T; Hayakawa Y; Kobayashi M; Takagane A; Hioki J
Gan To Kagaku Ryoho; 2007 Feb; 34(2):249-52. PubMed ID: 17301537
[TBL] [Abstract][Full Text] [Related]
12. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells.
Law KS; Chen HC; Liao SK
Anticancer Res; 2007; 27(2):841-50. PubMed ID: 17465210
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer.
Shimizu K; Watanabe S; Watanabe S; Matsuda K; Suga T; Nakazawa S; Shiratori K
Hepatogastroenterology; 2009; 56(89):240-4. PubMed ID: 19453066
[TBL] [Abstract][Full Text] [Related]
14. [Experimental studies on growth inhibition and regression of cancer metastases].
Chihara G
Gan To Kagaku Ryoho; 1985 Jun; 12(6):1196-209. PubMed ID: 4004287
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma.
Isoda N; Eguchi Y; Nukaya H; Hosho K; Suga Y; Suga T; Nakazawa S; Sugano K
Hepatogastroenterology; 2009; 56(90):437-41. PubMed ID: 19579616
[TBL] [Abstract][Full Text] [Related]
16. [A case of Stage IV non-operated advanced breast cancer with local recurrence thirteen years after initial therapy].
Morimoto Y; Imai S; Matsumoto T; Kunisue M; Kawasaki S; Yamaguchi K; Okabe M; Kawamoto K; Ito T; Ogasawara K
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1693-5. PubMed ID: 17940393
[TBL] [Abstract][Full Text] [Related]
17. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.
Adams M; Navabi H; Croston D; Coleman S; Tabi Z; Clayton A; Jasani B; Mason MD
Vaccine; 2005 Mar; 23(17-18):2374-8. PubMed ID: 15755631
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in immunopharmacology and therapeutic effects of polysaccharides.
Chihara G
Dev Biol Stand; 1992; 77():191-7. PubMed ID: 1426662
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies for recurrent ovarian cancer management.
Bhoola SM; Alvarez RD
Expert Rev Anticancer Ther; 2004 Jun; 4(3):437-48. PubMed ID: 15161442
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of ovarian cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin: effect of lymphadenectomy.
Hayashi A; Nishida Y; Yoshii S; Kim SY; Uda H; Hamasaki T
Cancer Sci; 2009 Oct; 100(10):1991-5. PubMed ID: 19656158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
